Furthermore, the expression of Col5a1 was increased in Glp1r VSM/ kidney and renal artery compared with Glp1r VSM+/+ tissue (Supplemental Figure 4, H and K)
Discontinuation was defined as lapse in GLP-1RA or BI prescription longer than 12 months
To learn more about optimizing thyroid medications, download my free eBook below
Clinical trials have demonstrated average weight loss of approximately 15% with semaglutide, 2022% with tirzepatide, and over 24% with retatrutide over the course of treatment
Patients are encouraged to stay hydrated, follow dietary recommendations, and ask questions to feel confident before starting their GLP-1 weight loss journey
In clinical trials, nausea occurred in 24-43% of patients across the 5-15 mg dose range, making it the most common side effect